aberrations and fit enough to tolerate FCR therapy, should be superior candidates for that latter, Along with the gain staying that this treatment might be done in six months whilst ibrutinib should be taken indefinitely.Are BTK and PLCG2 mutations necessary and enough for ibrutinib resistance in Long-term lymphocytic leukemia?Dengan melakukan rise